|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-5-24
|
|
pubmed:abstractText |
SPAG9 is a further new antigen that might be a candidate for clinical use. In particular the high frequency of mRNA expression in different solid tumours and haematological malignancies is a prerequisite for a potentially wide use. Most of the tested CML patients showed humoral immune responses against SPAG9. Nevertheless, specific CD8-positive T cell-responses and clinical efficacy analogue to the targets RHAMM or WT-1 have to be shown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
850-1
|
|
pubmed:meshHeading |
pubmed-meshheading:20359745-Adaptor Proteins, Signal Transducing,
pubmed-meshheading:20359745-Antibodies, Monoclonal,
pubmed-meshheading:20359745-Antigens, Neoplasm,
pubmed-meshheading:20359745-CD8-Positive T-Lymphocytes,
pubmed-meshheading:20359745-Cancer Vaccines,
pubmed-meshheading:20359745-Clinical Trials as Topic,
pubmed-meshheading:20359745-Combined Modality Therapy,
pubmed-meshheading:20359745-Drug Delivery Systems,
pubmed-meshheading:20359745-Drug Design,
pubmed-meshheading:20359745-Female,
pubmed-meshheading:20359745-Humans,
pubmed-meshheading:20359745-Immunotherapy, Active,
pubmed-meshheading:20359745-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:20359745-Male,
pubmed-meshheading:20359745-Vaccination
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
|
|
pubmed:publicationType |
Editorial,
Research Support, Non-U.S. Gov't
|
